Skip to main content

Peer Review reports

From: The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial

Original Submission
23 Sep 2022 Submitted Original manuscript
5 Nov 2022 Author responded Author comments - Haiyan Liu
Resubmission - Version 2
5 Nov 2022 Submitted Manuscript version 2
Publishing
11 Nov 2022 Editorially accepted
30 Nov 2022 Article published 10.1186/s12888-022-04388-y

You can find further information about peer review here.

Back to article page